Download the AJRR 2020 Annual Report

Data Shows Continuity of Hip and Knee Arthroplasty Trends and New Findings from Device-specific Survivorship Analyses

"The COVID-19 pandemic has led to unprecedented times in the United States and the world––yet the AJRR and the development of the AAOS family of registries continue to see unparalleled growth and expansion. This success is a tribute to the nation’s understanding of the fundamental importance of national registries, but also to the value that our registry brings to surgeons, hospitals and other stakeholders every day. Our procedural growth (over two million and counting) is rivaled by continued growth of data reuse opportunities for participation in multiple public and private value-based care incentive programs. I look forward to continued expansion and growth of all these opportunities."

-Bryan D. Springer, MD, FAAOS
AJRR Steering Committee Chair 

 

"As the definitive chronicle of joint replacement in the United States, this year's AJRR Annual Report continues to build on previous work and demonstrates the incredible value of the AJRR. More sophisticated and detailed survivorship curves have been included this year, including device-specific cumulative revision curves. The breadth of data reporting has also been expanded, and now includes analyses of topics such as type of anesthesia, discharge disposition, and body mass index."

-James A. Browne, MD, FAAOS
AJRR Publications Subcommittee Chair
and AJRR Publications Editor

 

Other AJRR 2020 Annual Report  highlights include:

  • Cumulative incidence of revision curves were used to examine survivorship.
  • Component specific statistical summaries have been added to this year’s report, displaying common components utilized in hip and knee arthroplasties as well as device-specific cumulative percent revision curves as presented in the AJRR 2019 Annual Report Supplement.
  • Additional opportunities for sites to track performance measurements and use Registry data in national quality improvement (QI) programs.
  • A 13% increase in patient-reported outcome measures (PROMs), compared to the previous year, through continued support of the RegistryInsights® PROM platform and partnerships with third party vendors with the expanded Authorized Vendor Program.
  • Peer-reviewed publications and presentations based on AJRR Registry data. 

.